- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05939830
Omission of ALND in Breast Cancer Patients With Axillary pCR
December 24, 2023 updated by: Jue Wang, The First Affiliated Hospital with Nanjing Medical University
Omission of Axillary Lymph Node Dissection in Breast Cancer Patients With Axillary Pathological Complete Response After Neoadjuvant Systemic Therapy
This prospective, single-arm, phase II trial studies axillary lymph node dissection (ALND) to see if it can be safely omitted in breast cancer patients with axillary pathological complete response (pCR) after neoadjuvant systemic therapy (NST).
Breast cancer patients with biopsy-proven positive axillary lymph nodes at initial diagnosis, and converted to negative after NST, which is confirmed by Stained region Lymph Node Biopsy(SrLNB), will be enrolled in the study.
In other words, a total of 92 patients will be exempted from ALND after SrLNB, and afterwards complete regional node irradiation (RNI) including the axilla.
They will also undergo adjuvant chemotherapy, targeted therapy, endocrinotherapy after surgery.
These patients will be followed up in the next three years for local-regional recurrence and long-time survival outcome.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
92
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jue Wang, MD
- Phone Number: +862568306360
- Email: wangjue200011@njmu.edu.cn
Study Contact Backup
- Name: Lingjun Ma, MD
- Phone Number: +8613186693728
- Email: malingjun@stu.njmu.edu.cn
Study Locations
-
-
-
Nanjing, China
- Recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Lingjun Ma
- Phone Number: +8613186693728
- Email: malingjun@stu.njmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female aged between 18 and 70 years;
- Pathologically confirmed invasive breast cancer (regardless of pathological type) with a clinical stage cT1-3;
- Pathologically confirmed positive axillary lymph nodes with a clinical stage of N1-3;
- Receiving a full course of neoadjuvant therapy (including neoadjuvant chemotherapy, neoadjuvant targeted therapy, neoadjuvant immunotherapy);
- Positive axillary lymph nodes successfully stained by carbon nanoparticles injection with/without titanium clip marking;
- All patients are required to undergo immunohistochemical staining for Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki- 67 proliferation index, and further fluorescence in situ hybridization (FISH) should be performed in HER2 2+ cases;
- Preoperative clinical assessment (including physical examination, imaging, with or without nomogram assessment) suggests positive axillary lymph nodes converted to negative (ycN0);
- ECOG score 0 - 1;
- Patients voluntarily participated in this study and signed the informed consent form
Exclusion Criteria:
- Bilateral breast cancer;
- Breast cancer during lactation period or pregnancy;
- Physical examination or imaging examination confirmed presence of distant metastases;
- Previous history of malignant tumor;
- History of previous surgery on the affected axilla; or history of surgery affecting the function of the upper extremity;
- History of radiation therapy to the breast or chest;
- Positive incision margins for breast-conserving surgery/mastectomy;
- Positive results of intraoperative rapid freeze pathology (including isolated tumor cells and micrometastases) for SrLNB (ypN+);
- Those who unable to complete the full course of follow-up adjuvant therapy as prescribed for various reasons;
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≥ 1.5 times the upper limit of normal, alkaline phosphatase(ALP) ≥ 2.5 times the upper limit of normal, total bile ≥ 1.5 times the upper limit of normal, serum creatinine ≥ 1.5 times the upper limit of normal; Left Ventricular Ejection Fractions (LVEF) < 50% in cardiac ultrasound;
- Severe coagulation dysfunction, serious systemic disease, or uncontrolled infection;
- Without personal freedom and independent civil capacity;
- Those with mental disorders, addictions, who were not eligible for enrollment in the judgment of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omit ALND
Omitting Axillary Lymph Node Dissection (ALND) in SrLNB-proven axillary complete response patients. Finishing regional lymph node irradiation (RNI) including the axilla after surgery. |
Before NST, positive lymph nodes would be marked with localized titanium clips under ultrasound guidance, and carbon nanoparticles suspension would be injected into the cortex of the marked lymph nodes and surrounding suspicious lymph nodes for staining.
Marked and stained lymph nodes will be removed and biopsied after NST.
RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
iDFS: invasive Disease-Free Survival after breast surgery
Time Frame: Up to 3 years after surgery
|
Time interval from the surgery to invasive local-regional recurrence, distant metastasis, contralateral invasive breast cancer, or death from any cause.
|
Up to 3 years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LRR: Local-Regional Recurrence after breast surgery
Time Frame: Up to 3 years after surgery
|
This includes both local and regional recurrences.
Local recurrence is defined as recurrence in the ipsilateral breast, chest wall, skin or surgical scar.
Regional recurrence is defined as recurrence in the affected lymphatic drainage area, including the axilla, supraclavicular region, subclavicular region, and internal mammary node area.
|
Up to 3 years after surgery
|
BCRL: Breast Cancer Related Lymphedema
Time Frame: Up to 3 years after surgery
|
Objective evaluation of upper limb lymphedema by arm circumference and bioelectrical impedance measurement.
In our study, BCRL is diagnosed in two ways:① Relative Volume Change (RVC ) >10% in the affected upper extremity.
②Bioelectrical impedance technology: the impedance ratio is defined as the ratio of the impedance of the healthy upper limb to the impedance of the affected upper limb, and BCRL is diagnosed when the patient's impedance ratio is higher than the mean + 2 standard deviations (SD) of healthy controls.
When the two measurements are inconsistent, the former results shall prevail.
|
Up to 3 years after surgery
|
Quality of life (QoL)
Time Frame: Up to 3 years after surgery
|
Patients' subjective assessment of quality of life (QoL) using the Functional Assessment of Cancer Therapy-Breast (FACT-B) .
FACT-B is divided into 36 items in 5 domains, namely: physical status (7 items), social/family status (7 items), emotional status (6 items), functional status (7 items) and additional concerns, and each item is classified into five levels: not at all (0), somewhat (1), somewhat (2), fairly (3) and very much (4).
Positive items were scored directly from 0 to 4, while negative items (i.e., the larger the number of response options, the worse the quality of life) were scored in reverse.
The total score of FACT-B scale ranges from 0 to 144, a higher score means a better quality of life for the patient.
|
Up to 3 years after surgery
|
Patient-reported arm morbidity
Time Frame: Up to 3 years after surgery
|
Patients' subjective assessment of lymphedema using the Quick Disability of the Arm, Shoulder, and Hand (Quick DASH) questionnaires,Quick DASH consists of 11 items, and is a self-rating scale of daily functioning including social functioning and physical activity and upper extremity symptoms.
Each item is divided into 5 levels, and the patient's score is calculated as score = [(patient score/number of response items) - 1] × 25, with a total score of 0 to 100, and the higher the score, the greater the degree of upper limb dysfunction.
|
Up to 3 years after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
July 1, 2023
First Submitted That Met QC Criteria
July 10, 2023
First Posted (Actual)
July 11, 2023
Study Record Updates
Last Update Posted (Estimated)
December 27, 2023
Last Update Submitted That Met QC Criteria
December 24, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SrLNB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Stained region Lymph Node Biopsy (SrLNB)
-
Duke UniversityCompletedProstate CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
Gangnam Severance HospitalCompletedNeoadjuvant Chemotherapy | Micrometastases
-
University of California, San FranciscoNational Institutes of Health (NIH)Recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingConjunctival Melanoma | Porocarcinoma | Ocular Surface Squamous Neoplasia | Merkel Cell Carcinoma, Unspecified | Ocular Sebaceous Carcinoma | Ocular Basal Cell CarcinomaItaly
-
Bulent Ecevit UniversityRecruiting
-
Professor Fernando Figueira Integral Medicine InstituteCompletedUterine Cervical Neoplasms | Uterine NeoplasmsBrazil
-
The Christie NHS Foundation TrustWithdrawnSquamous Cell Carcinoma of the Anus
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIC Skin Melanoma | Stage IV MelanomaUnited States
-
Jewish General HospitalMcGill University Health Centre/Research Institute of the McGill University...RecruitingSentinel Lymph Node | Cutaneous Squamous Cell CarcinomaCanada